The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome

Hilde Kelchtermans, Walid Chayoua, Bas de Laat*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Web of Science)

Abstract

The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPLs). Progress is being made in understanding the pathogenesis of the syndrome, but difficulties persist in the identification of patients at risk for thrombosis and/or pregnancy morbidity. Beta-2 glycoprotein I ( (2) GPI), a plasma protein consisting of five sushi domains, is thought to be the main antigenic target of aPLs. Antibodies recognizing domain I of (2) GPI are predominantly present in patients with an elevated risk of thrombosis, whereas antidomain IV/V antibodies are found in nonthrombotic autoimmune diseases. Indeed, domain I antibodies proved to be pathogenic in multiple studies. Retrospective studies have provided evidence for an added clinical value of antidomain I antibodies in the risk stratification of patients with APS. Still, wide ranges of odds ratio exist between studies, probably due to differences in the study and control population, and detection methods used. Despite the proven pathogenicity of antidomain I antibodies and their correlations with clinical manifestations of APS, heterogeneity of the current studies has prohibited their acceptance in the official diagnostic criteria. Well-designed large longitudinal prospective studies with available and new, preferentially functional, assays for the risk stratification of patients with APS are required.
Original languageEnglish
Pages (from-to)458-465
Number of pages8
JournalSeminars in Thrombosis and Hemostasis
Volume44
Issue number5
DOIs
Publication statusPublished - 1 Jul 2018

Keywords

  • antiphospholipid syndrome
  • 2 glycoprotein I
  • domain I antibodies
  • SYSTEMIC-LUPUS-ERYTHEMATOSUS
  • PROOF-OF-CONCEPT
  • BETA(2)-GLYCOPROTEIN I
  • IGG ANTIBODIES
  • ANTI-BETA(2)-GLYCOPROTEIN-I ANTIBODIES
  • ANTICARDIOLIPIN ANTIBODIES
  • ANTICOAGULANT ACTIVITY
  • CHEMILUMINESCENCE IMMUNOASSAY
  • INTERNATIONAL MULTICENTER
  • CLASSIFICATION CRITERIA

Cite this